Article Sidebar
Views PDF: 84
ANALYZING RISK FACTORS OF ADJUVANT VINORELBIN PLUS CISPLATIN CHEMOTHERAPY FOR THE TREATMENT OF STAGED IB-IIIA NON-SMALL CELL LUNG CANCER
Main Article Content
Abstract
Objective: Analyzing the prognostic factors in adjuvant chemotherapy with vinorelbine/cisplatin regimen in non-small cell lung cancer patients at K hospital from January 2017 to May 2022. Patients and method: Retrospective and prospective analysis of 66 patients with stage IB-IIIA resected non-small cell lung cancer received adjuvant vinorelbine plus cisplatin chemotherapy from K hospital, 01/2017 to 05/2022. Results: A total of 66 patients with stage IB to IIIA were enrolled, there were 6 patients with local recurrent (9.1%), 6 patients with distant metastasis (9.1%), six patients with local recurrent and distant metastasis (9.1%). The proportion of recurrence and metastasis after adjuvant chemotherapy was 27.3%. The average PFS was 29.10 ± 1.63 months, 31.8 ± 3.24 months in patients with performance status ECOG 0; and of 24.7 ± 2.92 months in patients with performance status ECOG 1 (p< 0.05). The percentage of 1-year PFS, 2-year PFS and 3-year PFS were 80.3%, 60.7% and 41.0% respectively. Patients in stage IB – II and IIIA has mean PFS of 17.7 ± 1.39 and 30.8 ± 2.66 (p< 0.05) respectively. Conclusion: The mean of progression-free survival (PFS) was 29,10 ± 1,63 months in patients with non-small cell lung carcinoma (NSCLC) stage IB – IIIB were underwent adjuvant therapy of vinorelbine/cisplatin. The disease stages and ECOG (Eastern cooperative Oncology Group) performance status were two prognostic factors significantly correlated with PFS.
Article Details
Keywords
Non-small cell lung cancer, vinorelbine/cisplatin, adjuvant chemotherapy.
References
2. National Comprehensive Cancer Network (NCCN) (2019). Non-small cell lung cancer. NCCN clinical practice guidelines in oncology v.6.2019. http://www.NCCN.com dowloads.
3. Phan Lê Thắng (2017), Nghiên cứu điều trị ung thư phổi không tế bào nhỏ giai đoạn II, IIIa bằng phối hợp phẫu thuật triệt căn và hóa - xạ trị bổ trợ, Luận án Tiến sĩ, Trường Đại học Y Hà Nội.
4. Douillard J.-Y., Rosell R., De Lena M. và cộng sự. (2006). Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol, 7(9), 719–727.
5. Winton T., Livingston R., Johnson D. và cộng sự. (2005). Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer. N Engl J Med, 352(25), 2589–2597.
6. Douillard J.-Y., Tribodet H., Aubert D. và cộng sự. (2010). Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol, 5(2), 220–228.
7. Stephens R., Brown J., Fairlamb D. và cộng sự. (2002). The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Br J Cancer, 86, S2–S2.
8. Scagliotti G.V. (2005). The ALPI trial: the Italian/European experience with adjuvant chemotherapy in resectable non–small lung cancer. Clin Cancer Res, 11(13), 5011s–5016s.
9. Kato H. (2004). Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med, 22, 1713–1721.
10. Le Chevalier T. (2003). Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): Cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (nsclc). journal of clinical oncology, amer soc clinical oncology 330 john carlyle st, ste 300, alexandria, va …, 238S-238S.